Profile: Rosetta Genomics Ltd (ROSG.O)
19 Dec 2014
Rosetta Genomics Ltd., incorporated on March 9, 2000, is seeking to develop and commercialize new diagnostic products based on a discovered group of genes known as microRNAs. The Company has established a clinical laboratory improvement amendment (CLIA)-certified laboratory in Philadelphia, which enables it to commercialize its own diagnostic tests applying its microRNA technology. Its Rosetta Cancer Origin Test is its second-generation microRNA-based diagnostic for the identification of the primary site of metastatic cancer, specifically metastatic cancer of unknown primary (CUP). Rosetta Mesothelioma Test leverages microRNA’s high-specificity as biomarkers to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura, a medically and legally important differential diagnosis.
The Company’s Rosetta Lung Cancer Test is a microRNA-based lung cancer classification test for cytology samples, mainly fine-needle aspirate (FNA), samples, as well as pathology samples, such as small biopsies and resections. Its Rosetta Kidney Cancer Test is a microRNA-based kidney tumor classification test for pathology samples. This test was designed to classify primary kidney tumors into one of the four most common types: the malignant renal cell carcinomas clear cell (conventional), papillary and chromophobe as well as the benign oncocytoma. The Company’s therapeutic pipeline consists of CMV Therapeutic, Rimonim Consortium and Magneton project.
The Company competes with Combimatrix Corporation, Alnylam Pharmaceuticals, Inc., Asuragen Inc., Exiqon A/S, Life Technologies Corporation, Isis Pharmaceuticals, Merck & Co., Inc., Santaris Pharma A/S and Regulus Therapeutics.
Rosetta Genomics Ltd
10 Plaut St., Science Park, POB